BG-12 is looking good but (personally) I hate to read reports about its projected success in investment advice sources. I'd rather learn its prospectus for helping PwMS than how much it has already boosted the portfolio of Biogen stock holders.
Everyone has a right to earn lots of money of course. Well, maybe not everyone - like those of us who hope to dump more money than we ever earned into purchasing BG-12 in hopes of retaining some quality of life.
Media reports are usually just as bad and even more inflammatory than MS itself. I'll stick to scientific/medical journals and inside info from my MS doc.
Sorry for the mini-vent - kind of. It’s just hard to be reminded that people are busy behind the scenes in the business of gambling for big profits on a maintenance treatment for the disease that has kept me from earning what I wanted in life - or even living the life I desired.
I truly hope new drugs and research will help those of you who are newer to this journey.
Sounds a bit like looking a gift horse in the mouth : - ) If there were no profit motive, then there would be no Tysabri, Avonex, Rebif, Copaxone, Betaseron etc. No one is going to develop these drugs for free.
Kyle
I don't get your meaning Kyle. I assure you that the moment a gift horse comes my way I will look it squarely in the mouth and offer a sincere nod of gratitude. As it happens, I've frequently mentioned in these pages just how grateful I am to have access to disease modifiers DESPITE their continuously escalating costs :-)
Looking a gift horse in the mouth? No, because I'm not ungrateful and my DMD is no free gift from a pharmaceutical company.
Yep, companies have every right to profit. In fact, anticipating anything less usually dooms business to failure. Who would want to deny them a big return on at least a few research risks? So I suspect Biogenic Idec will do just fine with this particular venture - to the benefit of manufacturer and consumer alike.
So please take another look at post. Maybe you'll see that my objection was to looking at financial journals for a review of medical information. My PERSONAL preference is to stay up-to-date on MS data through reports and evaluations offered in scientific and/or medical educational sources.
I've been following BG12 and the majority of the mentions of its efficacy and forward path in the FDA approval process does seem to come from the financial advisers who rate stocks as to whether investors should buy, hold or sell.
Right now they are all saying either buy or hold with Biogen Idec, because of the promise that BG12 will make lots of money.
There may be some new news on BG12 in the ECTRIMS video links I just posted. That would give the medical perspective.
As for me, I'll take the news wherever I can get it and then sort out the intent of the source as well as the reliability.
I should have added - you can set alerts to come to your email through
http://www.google.com/alerts
it is a great way to keep up on the news.
I'm with you Lulu. News is news. I'm to a believer int the Big Pharma is evil philosophy :-)
Kyle
That's just Mary being snarkey again! lol Love ya Mary!
I too am with you Lulu, the more news and info we get, the better. Personally I am keeping a digital file on Gilenya and BG12, which is sounding very promising. I am hoping it will get FDA approval soon and I truly pray the insurance companies and Biogen will allow it to be affordable.
Deb